Pascal Jezequel
Overview
Explore the profile of Pascal Jezequel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jezequel P, Gouraud W, Ben Azzouz F, Basseville A, Juin P, Lasla H, et al.
Bull Cancer
. 2021 Sep;
108(11):1057-1064.
PMID: 34561023
We are taking advantage of the launch of the latest version (v4.6) of our web-based data mining tool "breast cancer gene-expression miner" (bc-GenExMiner) to take stock of its position within...
12.
Colombie M, Jezequel P, Rubeaux M, Frenel J, Bigot F, Seegers V, et al.
BMC Cancer
. 2021 Apr;
21(1):333.
PMID: 33789635
Background: Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of...
13.
Jezequel P, Gouraud W, Ben Azzouz F, Guerin-Charbonnel C, Juin P, Lasla H, et al.
Database (Oxford)
. 2021 Feb;
2021.
PMID: 33599248
'Breast cancer gene-expression miner' (bc-GenExMiner) is a breast cancer-associated web portal (http://bcgenex.ico.unicancer.fr). Here, we describe the development of a new statistical mining module, which permits several differential gene expression analyses,...
14.
Nguyen J, Jezequel P, Gillois P, Silva L, Ben Azzouz F, Lambert-Lacroix S, et al.
Bioinformatics
. 2021 Feb;
37(15):2165-2174.
PMID: 33523112
Motivation: The principle of Breiman's random forest (RF) is to build and assemble complementary classification trees in a way that maximizes their variability. We propose a new type of random...
15.
Ben Azzouz F, Michel B, Lasla H, Gouraud W, Francois A, Girka F, et al.
Comput Biol Med
. 2020 Dec;
129:104171.
PMID: 33316552
Triple-negative breast cancer (TNBC) heterogeneity represents one of the main obstacles to precision medicine for this disease. Recent concordant transcriptomics studies have shown that TNBC could be divided into at...
16.
Jezequel P, Patsouris A, Guette C, Juin P, Campone M
J Natl Cancer Inst
. 2020 Mar;
112(8):863-864.
PMID: 32191300
No abstract available.
17.
Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, et al.
Cancer Res
. 2020 Feb;
80(3):639.
PMID: 32015158
No abstract available.
18.
Lohard S, Bourgeois N, Maillet L, Gautier F, Fetiveau A, Lasla H, et al.
Nat Commun
. 2020 Jan;
11(1):259.
PMID: 31937780
A fascinating but uncharacterized action of antimitotic chemotherapy is to collectively prime cancer cells to apoptotic mitochondrial outer membrane permeabilization (MOMP), while impacting only on cycling cell subsets. Here, we...
19.
Millour M, Charbonnel C, Magrangeas F, Minvielle S, Campion L, Gouraud W, et al.
Cancer Genomics Proteomics
. 2019 Aug;
3(2):89-95.
PMID: 31394686
Background: In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied empirically to all patients. The aim of this study was to...
20.
Valo I, Raro P, Boissard A, Maarouf A, Jezequel P, Verriele V, et al.
Proteomics
. 2019 Jul;
19(21-22):e1800446.
PMID: 31318138
Human olfactomedin-4 (OLFM4) is a secreted protein involved in a variety of cellular functions including proliferation, differentiation, apoptosis, and cell adhesion. OLFM4 expression has been studied in several tumor types...